CO6180443A2 - Antagonistas del receptor de progesterona - Google Patents

Antagonistas del receptor de progesterona

Info

Publication number
CO6180443A2
CO6180443A2 CO09050000A CO09050000A CO6180443A2 CO 6180443 A2 CO6180443 A2 CO 6180443A2 CO 09050000 A CO09050000 A CO 09050000A CO 09050000 A CO09050000 A CO 09050000A CO 6180443 A2 CO6180443 A2 CO 6180443A2
Authority
CO
Colombia
Prior art keywords
pregna
pentafluoro
hydroxy
phenyl
dien
Prior art date
Application number
CO09050000A
Other languages
English (en)
Spanish (es)
Inventor
Ulrike Fuhrmann
Anja Schmidt
Arwed Cleve
Orlin Petrov
Gunnar Garke
Stefan Pruehs
Margarete Brudny-Kloeppel
Antje Rottmann
Rainer Hasselmann
Marcus Schultze-Mosgau
Carsten Moeller
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CO6180443A2 publication Critical patent/CO6180443A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0081Substituted in position 17 alfa and 17 beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36Antigestagens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005Ketals
    • C07J21/006Ketals at position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CO09050000A 2006-11-15 2009-05-15 Antagonistas del receptor de progesterona CO6180443A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006054535A DE102006054535A1 (de) 2006-11-15 2006-11-15 Progesteronrezeptorantagonisten

Publications (1)

Publication Number Publication Date
CO6180443A2 true CO6180443A2 (es) 2010-07-19

Family

ID=39243738

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09050000A CO6180443A2 (es) 2006-11-15 2009-05-15 Antagonistas del receptor de progesterona

Country Status (40)

Country Link
US (1) US8053426B2 (cg-RX-API-DMAC7.html)
EP (1) EP2081951B1 (cg-RX-API-DMAC7.html)
JP (1) JP5260537B2 (cg-RX-API-DMAC7.html)
KR (1) KR101494914B1 (cg-RX-API-DMAC7.html)
CN (1) CN101541823B (cg-RX-API-DMAC7.html)
AR (1) AR063813A1 (cg-RX-API-DMAC7.html)
AT (1) ATE465169T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007321848B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0718409A2 (cg-RX-API-DMAC7.html)
CA (1) CA2669767C (cg-RX-API-DMAC7.html)
CL (1) CL2007003266A1 (cg-RX-API-DMAC7.html)
CO (1) CO6180443A2 (cg-RX-API-DMAC7.html)
CY (1) CY1110671T1 (cg-RX-API-DMAC7.html)
DE (2) DE102006054535A1 (cg-RX-API-DMAC7.html)
DK (1) DK2081951T3 (cg-RX-API-DMAC7.html)
EA (1) EA017038B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP099337A (cg-RX-API-DMAC7.html)
ES (1) ES2343915T3 (cg-RX-API-DMAC7.html)
GT (1) GT200900128A (cg-RX-API-DMAC7.html)
HN (1) HN2009000997A (cg-RX-API-DMAC7.html)
HR (1) HRP20100366T1 (cg-RX-API-DMAC7.html)
IL (1) IL198650A (cg-RX-API-DMAC7.html)
JO (1) JO2672B1 (cg-RX-API-DMAC7.html)
MA (1) MA30990B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009005212A (cg-RX-API-DMAC7.html)
NO (1) NO20092284L (cg-RX-API-DMAC7.html)
NZ (1) NZ576927A (cg-RX-API-DMAC7.html)
PA (1) PA8755801A1 (cg-RX-API-DMAC7.html)
PE (1) PE20081409A1 (cg-RX-API-DMAC7.html)
PL (1) PL2081951T3 (cg-RX-API-DMAC7.html)
PT (1) PT2081951E (cg-RX-API-DMAC7.html)
RS (1) RS51369B (cg-RX-API-DMAC7.html)
SI (1) SI2081951T1 (cg-RX-API-DMAC7.html)
SV (1) SV2009003260A (cg-RX-API-DMAC7.html)
TN (1) TN2009000185A1 (cg-RX-API-DMAC7.html)
TW (1) TW200831109A (cg-RX-API-DMAC7.html)
UA (1) UA98312C2 (cg-RX-API-DMAC7.html)
UY (1) UY30718A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008058767A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200904150B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) * 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) * 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
EP2868320A1 (en) 2013-11-03 2015-05-06 Flamina Holding AG A composition or group of compositions for the treatment of human cells
MX391191B (es) 2014-11-17 2025-03-21 Context Biopharma Inc Composiciones de liberación extendida de onapristona y métodos.
WO2017053793A1 (en) 2015-09-25 2017-03-30 Arno Therapeutics, Inc. Methods of making onapristone intermediates
MX2018007154A (es) 2015-12-15 2019-01-10 Context Biopharma Inc Composiciones de onapristona amorfa y metodos para hacer las mismas.
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
JP2019513706A (ja) * 2016-03-21 2019-05-30 コンテキスト・バイオファーマ・インコーポレイテッド オナプリストン代謝物質組成物及び方法
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
CN86102502B (zh) * 1986-08-29 1988-06-22 上海市计划生育科学研究所 11,17位双取代δ4,9-雌甾二烯化合物的合成方法
CA2100514C (en) * 1992-07-29 2005-03-29 Johannes A. M. Hamersma 17-spiromethylene steroids
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19535572B4 (de) * 1994-09-14 2007-02-01 Schering Ag Verfahren zur Herstellung von 17 α-Fluor-steroid-ketonen
DE69532894T2 (de) * 1994-11-22 2004-09-02 Balance Pharmaceuticals, Inc., Pacific Palisades Verfahren zur empfängnisverhütung
WO1998005679A2 (en) 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US20010016578A1 (en) * 1997-06-18 2001-08-23 Balance Pharmaceuticals, Inc. Compositions and methods for contraception and for treatment of benign gynecological disorders
DE19929715A1 (de) * 1999-06-24 2000-12-28 Schering Ag 11ß-langkettig-substituierte Estratriene, Verfahren zur Herstellung , pharmazeutische Präparate, die diese 11ß-langkettig-substituierten Estratriene enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE10049736A1 (de) * 2000-09-29 2002-04-18 Jenapharm Gmbh 17alpha-Fluoralkylsteroide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
IL154974A0 (en) * 2000-10-18 2003-10-31 Schering Ag Inhibition of the growth factor dependency of tumor cells
US20020143000A1 (en) * 2001-01-09 2002-10-03 Christa Hegele-Hartung Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
DE10221034A1 (de) * 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
DK1501859T3 (da) 2002-05-03 2006-03-06 Schering Ag 17 alfa-fluoralkyl- 11 beta-benzaldoxim-steroider, fremgangsmåde til fremstilling heraf, farmaceutiske præparater indeholdende disse steroider samt deres anvendelse til fremstilling af lægemidler
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten

Also Published As

Publication number Publication date
KR20090079995A (ko) 2009-07-22
ZA200904150B (en) 2010-11-24
DK2081951T3 (da) 2010-08-09
ATE465169T1 (de) 2010-05-15
JP5260537B2 (ja) 2013-08-14
SV2009003260A (es) 2009-12-14
ES2343915T3 (es) 2010-08-12
CN101541823A (zh) 2009-09-23
AR063813A1 (es) 2009-02-18
HN2009000997A (es) 2011-10-19
PE20081409A1 (es) 2008-12-05
IL198650A (en) 2012-05-31
CN101541823B (zh) 2012-10-03
US20080200440A1 (en) 2008-08-21
AU2007321848B2 (en) 2013-09-19
CY1110671T1 (el) 2015-06-10
AU2007321848A1 (en) 2008-05-22
KR101494914B1 (ko) 2015-02-23
UA98312C2 (en) 2012-05-10
JO2672B1 (en) 2012-06-17
CA2669767C (en) 2014-04-01
EP2081951A1 (en) 2009-07-29
CL2007003266A1 (es) 2008-07-04
PT2081951E (pt) 2010-07-01
DE102006054535A1 (de) 2008-05-21
CA2669767A1 (en) 2008-05-22
IL198650A0 (en) 2010-02-17
SI2081951T1 (sl) 2010-08-31
ECSP099337A (es) 2009-06-30
WO2008058767A1 (en) 2008-05-22
PL2081951T3 (pl) 2010-09-30
HK1136302A1 (en) 2010-06-25
UY30718A1 (es) 2008-07-03
GT200900128A (es) 2012-02-01
NO20092284L (no) 2009-08-13
BRPI0718409A2 (pt) 2013-12-17
MX2009005212A (es) 2009-05-27
PA8755801A1 (es) 2009-08-26
EA017038B1 (ru) 2012-09-28
DE602007006040D1 (de) 2010-06-02
HRP20100366T1 (hr) 2010-07-31
JP2010509386A (ja) 2010-03-25
TW200831109A (en) 2008-08-01
RS51369B (sr) 2011-02-28
TN2009000185A1 (en) 2010-10-18
MA30990B1 (fr) 2009-12-01
US8053426B2 (en) 2011-11-08
EA200900635A1 (ru) 2009-12-30
EP2081951B1 (en) 2010-04-21
NZ576927A (en) 2012-01-12

Similar Documents

Publication Publication Date Title
CO6180443A2 (es) Antagonistas del receptor de progesterona
CU20090085A7 (es) Antagonistas del receptor de progesterona
SG163585A1 (en) Melanocortin receptor ligands
DK2049475T3 (da) Cyclohexyl-substituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroid dehydrogenase1
DK2049513T3 (da) Piperidinylsubstituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1
IL194810A0 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
SI2021337T1 (sl) Inhibitorji beta hidroksisteroidne dehidrogenaze
BRPI0905785A2 (pt) Artigos absorventes compreendendo materiais absorventes exibindo desintumescimento/ reintumescimento
JP2010509386A5 (cg-RX-API-DMAC7.html)
DOP2012000015A (es) (11ß,17ß)–17–HIDROXI–11–[4–(METILSULFONIL)FENIL]–17–(PENTAFLUOROETIL)ESTRA–4,9–DIEN–3–ONA CON ACCIÓN ANTAGONISTA EN EL RECEPTOR DE PROGESTERONA
MX2009010552A (es) Antagonistas de receptor de opioide periferico y usos de los mismos.
CY1113071T1 (el) Καππα επιλεκτικος ανταγωνιστης οπιοειδους υποδοχεα
CO6241154A2 (es) "compuestos novedosos con accion agonista o antagonista del receptor 1 vainilloide 1 (vr1/trpv1)\"
EA201170795A1 (ru) Антагонисты ccr2 группы 4-азетидинил-1-гетероарил-циклогексанола
BRPI0513902A (pt) novos derivados de 4-benzilideno-piperidina
NO20084677L (no) Anvendelse av kombinasjonspreparater som inneholder trombinreseptorantagonister for behandling av hjerte-karforstyrrelser
MX2009013167A (es) Uso del factor de crecimiento de fibroblastos 7 (fgf7) y del receptor fgfr2b como biomarcadores.
BRPI0512376A (pt) piperazinodionas como antagonistas de receptor oxitocina
IN2012DN00764A (cg-RX-API-DMAC7.html)
ATE466853T1 (de) Cgrp-rezeptorantagonisten
ATE502936T1 (de) 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten
MX2008000874A (es) Metodos y composiciones para anticoncepcion de emergencia utilizando antagonistas del receptor de endotelina.
TH102720A (th) โพรเจสเทอโรนรีเซพเตอร์แอนตาโกนิสต์
DOP2009000112A (es) Antagonistas del receptor de progesterona
UA95769C2 (ru) N-замещенные пиперидины и их применение в качестве фармацевтических препаратов

Legal Events

Date Code Title Description
FG Application granted